What is Selkirk Pharma?
Selkirk Pharma operates as a specialized contract manufacturing organization (CMO) focused on the complex requirements of aseptic fill/finish processes. The company distinguishes itself through a purpose-built, state-of-the-art facility designed to optimize yield and ensure the integrity of critical medical products. By integrating advanced SKAN isolator technology and high-performance Bausch & Stroebel filling equipment, Selkirk Pharma addresses the industry's growing demand for reliable, unidirectional process flows. This infrastructure is engineered to meet stringent regulatory standards while providing scalable vial capacity for pharmaceutical clients navigating the transition from clinical development to commercial-scale production.
How much funding has Selkirk Pharma raised?
Selkirk Pharma has raised a total of $33M across 2 funding rounds:
Angel/Seed
$9M
Angel/Seed
$24M
Angel/Seed (2020): $9M, investors not publicly disclosed
Angel/Seed (2023): $24M, investors not publicly disclosed
Key Investors in Selkirk Pharma
Undisclosed Investor
An undisclosed investor participating in the funding round, focusing on long-term capital appreciation within the life sciences and pharmaceutical manufacturing sectors.
Undisclosed Investor
An undisclosed investor participating in the funding round, specializing in early-stage and growth-stage investments in high-tech medical infrastructure.
Undisclosed Investor
An undisclosed investor participating in the funding round, providing strategic backing to companies with critical roles in the pharmaceutical supply chain.
What's next for Selkirk Pharma?
With this major enterprise-level funding, Selkirk Pharma is poised to scale its manufacturing footprint and enhance its service offerings for global biopharma partners. The strategic allocation of this capital will likely focus on optimizing facility throughput and expanding the technical capabilities of its aseptic processing lines. As the pharmaceutical industry continues to prioritize supply chain resilience and high-yield manufacturing, Selkirk Pharma's commitment to advanced isolator technology and process efficiency positions it as a key player in the contract manufacturing landscape. Future growth will likely be driven by the firm's ability to maintain high-quality standards while meeting the increasing volume requirements of its diverse client base.
See full Selkirk Pharma company page
